This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.
Patients with histologically and/or cytologically confirmed malignancy.
Age ≥18 years at enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of ≥3 months.
Meeting the diagnostic criteria for cachexia (based on Fearon's criteria).
Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.
Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.
Patients with acquired immunodeficiency syndrome (AIDS).
Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.
Single group
Nanocrystalline Megestrol Acetate
DrugNanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.
Proportion of patients with improved appetite at Week 4 based on the A/CS-12 scale.
Proportion of patients with >5% increase in body weight from baseline at Week 4, Week 8, and Week 12.
Click on the lead sponsor to view all of their trials.
Changchun GeneScience Pharmaceutical Co., Ltd.
Lead sponsor
Henan Cancer Hospital
Collaborator
